Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.40 -1.1%	$19.18	$15.47 ▼ $36.37	$697.95M	1.47	182,271 shs	360,630 shs
DAWN Day One Biopharmaceuticals	$6.27	$7.23	$6.08 ▼ $16.76	$635.54M	-1.24	1.11 million shs	1.05 million shs
RCKT Rocket Pharmaceuticals	$6.27 -4.4%	$6.72	$4.55 ▼ $26.98	$669.55M	1.02	1.51 million shs	2.08 million shs
TLSA Tiziana Life Sciences	$1.58 +15.3%	$1.20	$0.63 ▼ $1.91	$184.62M	0.29	475,497 shs	866,786 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-1.11%	+5.37%	-3.23%	-24.64%	+2.56%
DAWN Day One Biopharmaceuticals	0.00%	+0.32%	-15.73%	-49.56%	-57.11%
RCKT Rocket Pharmaceuticals	-4.42%	-3.54%	-12.18%	-40.11%	-72.06%
TLSA Tiziana Life Sciences	+15.33%	+16.18%	+20.61%	+92.71%	+95.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	0.9811 of 5 stars	3.6	0.0	0.0	1.9	0.0	0.0
DAWN Day One Biopharmaceuticals	2.7481 of 5 stars	4.6	1.0	0.0	2.6	2.5	0.0
RCKT Rocket Pharmaceuticals	4.9076 of 5 stars	4.5	3.0	4.7	4.0	5.0	0.6
TLSA Tiziana Life Sciences	0.4988 of 5 stars	0.0	5.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	92.58% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	387.58% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$37.73	501.71% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, RCKT, AVBP, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/16/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $30.00
5/16/2025	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $32.00
5/16/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/12/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $51.00
5/12/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
5/9/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$54.00 ➝ $45.00
5/9/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $44.00
5/9/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
DAWN Day One Biopharmaceuticals	$161.92M	3.92	N/A	N/A	$3.98 per share	1.58
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	N/A
DAWN Day One Biopharmaceuticals	-$188.92M	-$0.71	N/A	N/A	N/A	N/A	-22.40%	-19.79%	7/8/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)
TLSA Tiziana Life Sciences	-$17.69M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest TLSA, RCKT, AVBP, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/25/2025	Q4 2024	DAWN Day One Biopharmaceuticals	-$0.35	-$0.69	-$0.34	-$0.69	$27.11 million	$29.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
DAWN Day One Biopharmaceuticals	N/A	14.62	14.55
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
TLSA Tiziana Life Sciences	N/A	0.85	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
DAWN Day One Biopharmaceuticals	87.95%
RCKT Rocket Pharmaceuticals	98.39%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
DAWN Day One Biopharmaceuticals	6.20%
RCKT Rocket Pharmaceuticals	24.76%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
DAWN Day One Biopharmaceuticals	60	101.36 million	92.38 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	63.43 million	Optionable

TLSA, RCKT, AVBP, and DAWN Headlines

Recent News About These Companies

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23 at 10:59 AM | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23 at 7:00 AM | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.com

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab

April 3, 2025 | markets.businessinsider.com

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins

April 2, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

April 2, 2025 | globenewswire.com

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS

March 25, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, RCKT, AVBP, and DAWN Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.40 -0.23 (-1.11%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$20.40 0.00 (0.00%)

As of 05/23/2025 04:02 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.27 0.00 (0.00%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$6.30 +0.03 (+0.46%)

As of 05/23/2025 07:57 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$6.27 -0.29 (-4.42%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$6.28 +0.01 (+0.08%)

As of 05/23/2025 07:46 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Tiziana Life Sciences NASDAQ:TLSA

$1.58 +0.21 (+15.33%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.02 (-1.27%)

As of 05/23/2025 07:55 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time